Hyperthermia combined with immune checkpoint inhibitor therapy: Synergistic sensitization and clinical outcomes
Sign Up to like & getrecommendations! Published in 2022 at "Cancer Medicine"
DOI: 10.1002/cam4.5085
Abstract: Within the field of oncotherapy, research interest regarding immunotherapy has risen to the point that it is now seen as a key application. However, inherent disadvantages of immune checkpoint inhibitors (ICIs), such as their low… read more here.
Keywords: checkpoint inhibitor; immune checkpoint; combined immune; hyperthermia combined ... See more keywords
Feasibility of supervised telehealth exercise for patients with advanced melanoma receiving checkpoint inhibitor therapy.
Sign Up to like & getrecommendations! Published in 2023 at "Cancer medicine"
DOI: 10.1002/cam4.6091
Abstract: PURPOSE To determine the feasibility, safety and preliminary efficacy of a telehealth supervised exercise programme in patients with advanced melanoma receiving checkpoint inhibitor therapy. METHODS A 8-week non-randomised feasibility pilot trial utilising a telehealth delivered… read more here.
Keywords: advanced melanoma; checkpoint inhibitor; patients advanced; telehealth ... See more keywords
SGLT2 inhibitor therapy for transthyretin amyloid cardiomyopathy: early tolerance and clinical response to dapagliflozin
Sign Up to like & getrecommendations! Published in 2022 at "ESC Heart Failure"
DOI: 10.1002/ehf2.14188
Abstract: Sodium‐glucose cotransporter 2 inhibitors (SGLT2i) improve clinical outcomes in heart failure patients with reduced and preserved left ventricular ejection fraction (LVEF), but have not yet been investigated in transthyretin amyloid cardiomyopathy (ATTR‐CM). This study aimed… read more here.
Keywords: amyloid cardiomyopathy; inhibitor therapy; transthyretin amyloid; sglt2 inhibitor ... See more keywords
Twelve cases of acneiform eruptions while on anti-CTLA4 therapy
Sign Up to like & getrecommendations! Published in 2020 at "Supportive Care in Cancer"
DOI: 10.1007/s00520-020-05381-5
Abstract: We present the first detailed report of acneiform eruptions in patients on CTLA-4 inhibitor therapy. Acneiform eruptions commonly occur (up to 75–100%) as a cutaneous adverse event associated with EGFR inhibition; however, acneiform eruptions have… read more here.
Keywords: ctla inhibitor; inhibitor therapy; acneiform eruptions; cutaneous adverse ... See more keywords
Tight metabolic control plus ACE inhibitor therapy improves GSD I nephropathy
Sign Up to like & getrecommendations! Published in 2017 at "Journal of Inherited Metabolic Disease"
DOI: 10.1007/s10545-017-0054-2
Abstract: The onset of microalbuminuria (MA) heralds the onset of glomerulopathy in patients with glycogen storage disease (GSD) type I. Unlike tubulopathy, which responds to improved metabolic control, glomerulopathy in GSD I is considered refractory to… read more here.
Keywords: ace inhibitor; gsd; metabolic control; inhibitor therapy ... See more keywords
Combination checkpoint inhibitor therapy induces multiple immune major related adverse events in the treatment of vaginal melanoma: A cautionary case report
Sign Up to like & getrecommendations! Published in 2019 at "Gynecologic Oncology Reports"
DOI: 10.1016/j.gore.2019.100508
Abstract: Highlights • As more ICIs are approved, better education is needed for patients and providers.• Major irAEs, signs of worsening immune toxicity, can present with benign symptoms.• IrAEs should be considered when patients on ICIs… read more here.
Keywords: inhibitor therapy; therapy induces; treatment; combination checkpoint ... See more keywords
Clinical outcome of concomitant vs interrupted BRAF inhibitor therapy during radiotherapy in melanoma patients
Sign Up to like & getrecommendations! Published in 2018 at "British Journal of Cancer"
DOI: 10.1038/bjc.2017.489
Abstract: This corrects the article DOI: 10.1038/bjc.2017.85 read more here.
Keywords: concomitant interrupted; inhibitor therapy; braf inhibitor; interrupted braf ... See more keywords
scRNA-seq in medulloblastoma shows cellular heterogeneity and lineage expansion support resistance to SHH inhibitor therapy
Sign Up to like & getrecommendations! Published in 2019 at "Nature Communications"
DOI: 10.1038/s41467-019-13657-6
Abstract: Targeting oncogenic pathways holds promise for brain tumor treatment, but inhibition of Sonic Hedgehog (SHH) signaling has failed in SHH-driven medulloblastoma. Cellular diversity within tumors and reduced lineage commitment can undermine targeted therapy by increasing… read more here.
Keywords: medulloblastoma; shh; cell; inhibitor therapy ... See more keywords
Risk of herpes zoster with IL-17 inhibitor therapy for psoriasis and other inflammatory conditions
Sign Up to like & getrecommendations! Published in 2019 at "Journal of Dermatological Treatment"
DOI: 10.1080/09546634.2019.1597246
Abstract: Abstract Background: Psoriasis is a chronic inflammatory skin disease that has been associated with a significantly higher risk of herpes zoster (HZ). Several newer biologics such as secukinumab, ixekizumab, and brodalumab inhibit IL-17 and have… read more here.
Keywords: inhibitor therapy; herpes zoster; zoster inhibitor; psoriasis ... See more keywords
Efficacy and safety of angiogenesis inhibitors in melanoma: a meta-analysis of seven randomized controlled trials
Sign Up to like & getrecommendations! Published in 2022 at "Melanoma Research"
DOI: 10.1097/cmr.0000000000000812
Abstract: Little is known about the efficacy and safety of angiogenesis inhibitor therapy in patients with melanoma. The objective of this study was to assess the possible benefits and harms of angiogenesis inhibitor therapy in patients… read more here.
Keywords: efficacy safety; inhibitor therapy; angiogenesis inhibitor;
Secukinumab for patients failing previous tumour necrosis factor‐α inhibitor therapy: results of a randomized open‐label study (SIGNATURE)
Sign Up to like & getrecommendations! Published in 2019 at "British Journal of Dermatology"
DOI: 10.1111/bjd.18623
Abstract: Efficacy data on therapies for patients with psoriasis who have failed tumour necrosis factor (TNF)‐α inhibitor therapy is limited. read more here.
Keywords: necrosis factor; inhibitor therapy; tumour necrosis;